October 20, 2020 | NF1, Neurofibromatosis, campaign, creativity
The Childhood Tumour Trust and Havas Lynx Group have launched a campaign to raise awareness and funds for people living with a rare genetic condition, neurofibromatosis 1 (NF1).
The Childhood Tumour Trust and Havas Lynx Group have launched a campaign to raise awareness and funds for people living with a rare genetic condition, neurofibromatosis 1 (NF1).
As part of the Health For All initiative from Havas Lynx Group – aiming to change inequality within healthcare by removing bias and stereotypes, shifting misconceptions, and challenging stigma – The Childhood Tumour Trust and Havas Lynx Group are aiming to get people talking about a condition that you’ll struggle to even pronounce.
NF1 is a genetic condition causing tumours to grow on nerve endings in children and young people, its symptoms can have a huge physical and psychological impact on those affected. It’s more prevalent than Cystic Fibrosis, Duchenne Muscular Dystrophy, and Huntington’s Disease combined – yet is much less known.
The campaign ‘Hard to say’ aims to change this. By showing unusual ways in which NF1 can sometimes be mispronounced, the campaign aims to put NF1 in the spotlight to raise awareness and funds to help those living with the condition.
“This is a really innovative and interesting campaign and has the potential to really propel neurofibromatosis to be a household name, increased visibility of NF1 is so vital to people living with the condition and those that support them.”
Dr Carly Jim, trustee of CTT and Senior Lecturer in Psychology at Manchester Metropolitan University
“One of the first problems we realised when trying to get people talking about NF1 was the name itself. By creating a campaign that faces this head on, we hope to finally raise some much-needed awareness for NF1. The more we can get people talking about the condition, the more we can help those affected by it.”
John McPartland – Creative Director Havas Lynx Group
About Childhood Tumour Trust
Childhood Tumour Trust is a growing charity whose aim is to bring children, young people and their families affected by neurofibromatosis type 1 (NF1) together, (be it virtually at the moment), provide online parental support, campaign for better care & earlier diagnosis and to liaise with schools over special educational support.
This content was provided by Havas Lynx
Company Details
Latest Content from Havas Lynx
How Pharma Companies Can Survive the Patent Cliff Through Digital Innovation
Manchester based healthcare communications agency, Havas lynx, has launched its annual white paper campaign, which this year promotes the vital need to support the growing number of carers in our...
On 16th April we met with a group of leading healthcare professionals and technology experts to learn more about how the new wave of cancer treatments are affecting everyday practice...
On 16th April we met with a group of leading healthcare professionals and technology experts to learn more about how the new wave of cancer treatments are affecting everyday practice...
On 8th March 2018, we held our oncology caregivers focus group to discuss the role of a cancer caregiver in today's care continuum, the challenges they face and potential solutions...
On 8th March 2018, we held our oncology caregivers focus group to discuss the role of a cancer caregiver in today's care continuum, the challenges they face and potential solutions...
On 22nd February we held our patient experience focus group, which brought together patients, doctors and industry advocates to discuss the changing landscape and challenges facing cancer care today. In...
On 22nd February we held our patient experience focus group, which brought together patients, doctors and industry advocates to discuss the changing landscape and challenges facing cancer care today. "We...
We bring together the experts. The patients. The scientists. The technologists. The creatives. We unite powerful insights to make science mean something real. We are stronger together. We are Switched...
Matching unprecedented clinical advances in immuno-oncology with transformative communication